|10th July 2014
Businesses should be investing both time and resource into ensuring that their digital assets comply with web accessibility standards. By now, most countries have introduced laws which require all communication to be accessible to people with disabilities; however inclusive design isn't just about removing the barriers that prevent access to websites by people with disabilities. Inclusive design has to consider the UX story for users of all abilities, across all platforms. Simply put: the more accessible your website is, the more people will be able to use it successfully. Accessibility in design is not just about people with permanent disabilities. Other factors needs to be considered such as:
Whatever the end goal is, whether you’re looking for users to complete a purchase, registration, or download, it’s our responsibility as business owners to ensure that everyone can complete that goal successfully. User-centric design is vital, apart from being a legal requirement, it also ensures that your digital assets provide the best quality experience for all users, which is why accessibility should be firmly embedded into all stages of your design process. There are other benefits to improved website accessibility, namely: reduced page sizes mean faster loading times, improved SEO which can help with higher organic rankings, and kudos from the online community (which can only help boost your brand reputation).
If you’d like to discuss how we can help you meet your own challenges, call us on +44 203 328 1840 or email us at firstname.lastname@example.org.
|14th July 2020
Blue Latitude Health, and our parent company Fishawack Health, have developed exclusive intellectual property, processes and tools to ensure you’re engaging customers in the right way. View our service one-pagers below to find out how we can help solve your challenges whether you’re in a medical, brand, portfolio or an above brand role.
|22nd June 2020
Despite facing worse health outcomes, minority populations are often left out of clinical trials and miss the opportunity to participate in life-saving research. Associate Consultant Ling Song explores this issue and calls for the pharmaceutical industry to change its approach.